Development of effervescent tablets containing benznidazole complexed with cyclodextrin

Journal of Pharmacy and Pharmacology

Volumn 63, Issue 6, 2011, Pages 786-793

  Maximiano, Flávia Pires ^a   Costa, Guilherme Hideki Yoshizane ^a   De Sá Barreto, Lívia Cristina Lira ^b   Bahia, Maria Terezinha ^a   Cunha Filho, Marcílio S S ^b  

^a FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

^b FEDERAL UNIVERSITY OF MATO GROSSO   (Brazil)

Author keywords

benznidazole; bioavailability; dissolution rate; effervescent tablets; factorial design

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; BENZNIDAZOLE; CYCLODEXTRIN; WATER;

ARTICLE; CONTROLLED STUDY; DRUG SOLUBILITY; DRUG STABILITY; EFFERVESCENT TABLET; FACTORIAL DESIGN; PHYSICAL CHEMISTRY; QUANTITATIVE ANALYSIS; SOLID STATE; TABLET DISINTEGRATION TIME; TABLET FORMULATION;

BETA-CYCLODEXTRINS; BIOLOGICAL AVAILABILITY; CHAGAS DISEASE; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; NITROIMIDAZOLES; SOLUBILITY; TABLETS; TECHNOLOGY, PHARMACEUTICAL; WATER;

EID: 79956225339     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2011.01284.x     Document Type: Article

References (24)

1. Caldas S, et al,. Trypanosoma cruzi: acute and long-term infection in the vertebrate host can modify the response to benznidazole. Exp Parasitol 2008; 118: 315-323. (Pubitemid 351174143)
2. Francisco AF, et al,. Trypanosoma cruzi: effect of benznidazole therapy combined with the iron chelator desferrioxamine in infected mice. Exp Parasitol 2008; 120: 314-319.
3. Lamas M, et al,. Development of parenteral formulations and evaluation of the biological activity of the trypanocide drug benznidazole. Int J Pharm 2006; 307: 239-243. (Pubitemid 41820420)
4. Morilla MJ, et al,. Intravenous liposomal benznidazole as trypanocidal agent: increasing drug delivery to liver is not enough. Int J Pharm 2004; 278: 311-318. (Pubitemid 38759504)
5. Silva JJN, et al,. Complexation of the anti-Trypanosoma cruzi drug benznidazole improves solubility and efficacy. J Med Chem 2008; 51: 4104-4114. (Pubitemid 352032438)
6. Leonardi D, et al,. Development of novel formulations for Chagas' disease: optimization of benznidazole chitosan microparticles based on artificial neural networks. Int J Pharm 2009; 367: 140-147.
7. Loftsson T, Brewster ME,. Pharmaceutical applications of cyclodextrins: basic science and product development. J Pharm Pharmacol 2010; 62: 1607-1621.
8. Cunha-Filho MSS, et al,. Characterization of β-lapachone and methylated β-cyclodextrin solid-state systems. AAPS PharmSciTech 2007; 8: Article 60.
9. Aulton ME,. Aulton's Pharmaceutics: The Design and Manufacture of Medicines, 3rd edn. London: Elsevier, 2007.
10. Kettaneh-Wold N,. Use of experimental design in the pharmaceutical industry. J Pharm Biomed Anal 1991; 9: 605-610.
11. Silva ALM, et al,. Development of an hplc analytical method for benznidazol tablets for the treatment of chagas disease. Quim Nova 2007; 30: 1163-1166.
12. FDA. Guidance for Industry-Dissolution Testing of Immediate Release Solid Oral Dosage Forms. Rockville: FDA, 1997.
13. USP 30. The United States Pharmacopeia, 30th edn. Rockville: United States Pharmacopeial Convention, 2008.
14. Khan KA, Rhodes CT,. Effect of compaction pressure on the dissolution efficiency of some direct compression systems. Pharm Acta Helv 1972; 47: 594-607.
15. Callahan JC, et al,. Equilibrium moisture content of pharmaceutical excipients. Drug Dev Ind Pharm 1982; 8: 355-369.
16. Greenspan L,. Humidity fixed points of binary saturated aqueous solutions. J Res Nat Bur Stand 1977; 81A: 89-96.
17. Maximiano FP,. [Physicochemical characterization of antichagasic benznidazole]. Quim Nova 2010; 33: 1714-1719 [in Portuguese].
18. Szejtli J,. Past, present, and future of cyclodextrin research. Pure Appl Chem 2004; 76: 1825-1845.
19. Aleem O, et al,. Effect of β-cyclodextrin and hydroxypropyl β-cyclodextrin complexation on physicochemical properties and antimicrobial activity of cefdinir. J Pharm Biomed Anal 2008; 47: 535-540.
20. Govindarajan R, Nagarsenker MS,. Influence of preparation methodology on solid-state properties of an acidic drug-cyclodextrin system. J Pharm Pharmacol 2004; 56: 725-733. (Pubitemid 38801688)
21. Fernandes CM, et al,. Physicochemical characterization and in vitro dissolution behavior of nicardipine cyclodextrins inclusion compounds. Eur J Pharm Sci 2002; 15: 79-88. (Pubitemid 34136971)
22. Ozer AY, et al,. Evaluation of the stability of commercial effervescent ascorbic acid tablets by factorial design. STP Pharma Sci 1993; 3: 313-317. (Pubitemid 23255889)
23. Saharan VA, et al,. Dissolution enhancement of drugs part II: effect of carriers. Int J Health Res 2009; 2: 207-223.
24. Amela J, et al,. Effervescent tablets of ascorbic acid. I. Physical study of the possible components to be used. Drug Dev Ind Pharm 1996; 22: 407-416. (Pubitemid 26170094)